Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder

Takuya Masui, Ryota Hashimoto, Ichiro Kusumi, Katsuji Suzuki, Teruaki Tanaka, Shin Nakagawa, Tatsuyo Suzuki, Nakao Iwata, Norio Ozaki, Tadafumi Kato, Hiroshi Kunugi, Tsukasa Koyama

Research output: Contribution to journalArticlepeer-review

47 Citations (Scopus)

Abstract

Lithium is a first-line agent for the treatment of bipolar disorder. A significant association between the Val66Met polymorphism of the brain-derived neurotrophic factor gene and bipolar disorder has been reported. We investigated whether this polymorphism is associated with the response to lithium treatment in Japanese patients with bipolar disorder. Patients had been treated with lithium carbonate for more than 1 year, and the response was retrospectively evaluated. No significant differences were found in the genotype distribution or allele frequency between responders and non-responders. Our results suggested that the brain-derived neurotrophic factor Val66Met polymorphism might not greatly contribute to the efficacy of lithium in bipolar disorder.

Original languageEnglish
Pages (from-to)49-50
Number of pages2
JournalPsychiatric Genetics
Volume16
Issue number2
DOIs
Publication statusPublished - 04-2006

All Science Journal Classification (ASJC) codes

  • Genetics
  • Genetics(clinical)
  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint

Dive into the research topics of 'Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder'. Together they form a unique fingerprint.

Cite this